Mechanism Of Action: The B cell receptor (BCR) pathway regulates lots of cellular processes including, proliferation, differentiation, and apoptosis which are essential for the functioning

Mechanism Of Action: Palbociclib is a CDK4/6 inhibitor that acts by binding to the ATP pocket. The CDK4/6 kinase is involved in the G1-S transition, so,

Mechanism Of Action: Gefitinib is an EGFR tyrosine kinase inhibitor that binds to the ATP-binding site of the enzyme. It is the first selective inhibitor

Mechanism Of Action: Sunitinib is a small molecule that inhibits multiplereceptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and

Mechanism Of Action: Erlotinib is belonged to the group ‘EGFR inhibitors’. It can block EGFRs, which is found on some tumor cells, as a result

Mechanism Of Action: Nilotinib can inhibit the tyrosine kinase activity of the BCR-ABL protein; CML is caused by the BCR-ABL oncogene. Nilotinib can overcome resistance

Mechanism Of Action: Sorafenib has demonstrated decreased tumor cell proliferation in vitro. It was shown to inhibit multiple intracellular (c-CRAF, BRAF, and mutant BRAF) and

Mechanism Of Action: Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia

Mechanism Of Action Letrozole: Letrozole works by blocking the enzyme aromatase, which turns the hormone androgen into small amounts of estrogen in the body, leads